Deleted Tweets From Scott Gottlieb, R-D.C.

Safety and innovation for medical devices should go hand in hand. I believe the best technological advances should lead to more lives saved and fewer adverse events: https://t.co/ffiK7ELkOp So we’re creating new incentives for innovation that improves saf

#FDA is focused on striking right balance between reducing new opioid addiction and providing appropriate access to pain medicines. To address these goals/challenges, #FDA is holding a meeting on 7/9 focused solely on needs of those suffering chronic pain

Since establishing the Opioid Policy Steering Committee a year ago, #FDA has received wide range of feedback, including patient voices, affirming that as we address this crisis we cannot lose sight of the needs those living with chronic/end-of-life pain:

Evidence-based information to inform opioid prescribing can help curb overprescribing, maintain access to needed treatments. We’ll be taking new steps to encourage medical professional societies to develop guidelines on appropriate prescribing: https://t.

RT @ikeswetlitz: .@US_FDA will start naming companies that have been accused of slowing down generic drug development (but will not… https://t.co/tHybwD069b

RT @BioCentury: FDA will identify companies that have abused REMS agreements to thwart generic, biosimilar competition,… https://t.co/io3mEHU9hM

RT @JaredSHopkins: Obviously best sock game in all of government https://t.co/bmCUgxHv3t QT @EricTopol: When you're the @US_FDA Commissioner [@SGottliebFDA], your socks get noticed :-) https://t.co/5pigRV53aM https://t.co/E3y1ilZ8c4)

RT @steveusdin1: FDA is reorganizing the Office of New Drugs to stay ahead of drug development. Now posted in front of the paywall -… https://t.co/pU9QznhhTy

These are my skinniest socks. https://t.co/avFsOAn6w0 QT @EricTopol: When you're the @US_FDA Commissioner [@SGottliebFDA], your socks get noticed :-) https://t.co/5pigRV53aM https://t.co/E3y1ilZ8c4)

#FDA will unveil in June a major updating of the structure and function of its new drug review process to make it more modern, rigorous, to better integrate cross disciplinary science as part of collaborative teams, develop more focused review divisions

RT @SeemaCMS: Catch me LIVE tomorrow with @WashingtonPost discussing the future of #Medicaid and its effects on American health.… https://t.co/OkWgwDFs7y

RT @FDATobacco: If nobody smoked, 1 out of every 3 cancer deaths in the U.S. could be prevented. #DearFutureMe #NPW2018 https://t.co/59BrDf7aoG

RT @SeemaCMS: For the first time ever, the @CMSGov Drug Pricing Dashboard will now show year-over-year price changes for prescrip… https://t.co/vxf2ps10eG

RT @califf001: Important step forward. Modernizing without losing the demand for high quality evidence! https://t.co/XFHQaeGtmV QT @SGottliebFDA: #FDA will unveil in June a major updating of the structure and function of its new drug review process to make it m… https://t.co/FhXK1mowUe)

Make sure that any gene therapy has either been approved by FDA or is being studied under appropriate regulatory oversight. Get the facts: Learn more about gene therapy and how it works. https://t.co/qrwgTWuCsZ

#FDA is concerned about the safety risks involved in “DIY” gene therapy products intended for self-administration and “do it yourself” kits to produce gene therapies for self-administration. We warned the sale of these products is against the law. https:/

Learn about the participation of women in clinical trials for cardiovascular drugs in our new journal article. Read here: https://t.co/rHCGBWzr0j @JACCJournals #JACC #FDAGreatDebate https://t.co/YASsRuZIWE

#FDA is focused on the risks posed to Americans from drugs brought illegally into US; increasing FDA’s presence at IMFs, improving our intelligence gathering, increasing collaboration with partners. New funding and authorities will support these efforts h

RT @FDAWomen: Thank you to everyone who joined “The Great Debate: What is Enough… Women in Clinical Trials” webcast today! Learn… https://t.co/si5H8Ct9NR

While CDC recently updated the case count for the salmonella outbreak in eggs, these are old cases meaning the last new illness was from last month (April 14, 2018). https://t.co/JnRtLB9ZMN

#FDA inspected Rose Acre Farms last month and the company is taking corrective action. FDA is monitoring to ensure the appropriate action takes place. https://t.co/JnRtLB9ZMN

Federal health officials updated consumer advice today because it is highly unlikely that romaine lettuce from the Yuma growing region is still in the supply chain: https://t.co/We02xgGjGj

FDA & CDC remind consumers to not eat any of the recalled eggs from Rose Acre Farms. These eggs were recalled April 13 & 16 so stores should not have them for purchase. Eggs last about three weeks - consumers should check they don’t have recalled

We know romaine lettuce has not been shipped from the Yuma area since mid-April. Consumers can be confident that romaine currently available for purchase is not part of this outbreak investigation: https://t.co/We02xgGjGj

#FDA ruled out that the contamination was caused by just one farm suggesting it was a complex problem and will take further time to investigate https://t.co/We02xgGjGj Our goal is to find the source of this outbreak. We’ll use what we learn to improve our

RT @HHSMedia: HHS @SecAzar praises @US_FDA approval of first non-opioid treatment for opioid withdrawal https://t.co/x7R2uATqCb #opioids

#FDA is taking policy steps to help promote the development of new treatments for opioid addiction, to promote the use of MAT, and to address the stigma sometimes associated with safe and effective replacement therapy. Stigma can be a barrier to their use

RT @FDAWomen: Read @SGottliebFDA's full remarks from today's #FDAGreatDebate: https://t.co/pUZoZBY1G1

RT @ABC: "We will never see his like again": 81-year-old whose blood donations have helped save over 2 million babies donate… https://t.co/M85PMSwBFR

RT @NIIMBL: @US_FDA Deputy Commissioner for Policy, Legislation, and Analysis, Anna Abram, discusses FDA support for the develo… https://t.co/WTPoYOc4fr

https://t.co/97a8BXqndi

RT @FDATobacco: Today, FDA sent official information requests to four e-cig manufacturers. The companies must respond by July 12… https://t.co/pvFKvkSiJr

RT @FDAMedia: FDA requires additional e-cigarette makers to provide critical information so the agency can better examine youth u… https://t.co/9kMGpEpGiZ

@alikodjakNPR @sangerkatz @PeterSullivan4 @porszag @SecAzar But our discussion was about Part D. In Part D people choose plans in a large marketplace. Even in the employer ASO market there’s choice. True sometimes employers only offer a single option, but

The letters to more e-cigarette makers follow a similar request #FDA sent to JUUL Labs last month. We’ll explore all regulatory options, including enforcement actions, based on what we learn from the information these manufacturers are required to provide

RT @FDAMedia: Statement from @SGottliebFDA on new agency efforts to shine light on situations where drug makers may be pursuing g… https://t.co/pmd86YTlgb

Too many kids continue to experiment with e-cigarette and vaping products, and it’s critical that we take aggressive steps to address it. This includes taking a hard look at whether certain design features/product marketing practices are fueling youth use

Today #FDA is continuing to take important steps under our Youth Tobacco Prevention Plan by requiring four additional e-cigarette makers to provide critical information so the agency can better examine youth use and product appeal: https://t.co/KdVzyo6YbU

@alikodjakNPR @sangerkatz @PeterSullivan4 @porszag @SecAzar The bigger change we’ve seen in recent years, IMHO, is the wider adoption of “closed” formularies. I don’t have data but am pretty sure they’re far more common today than they were pre-ACA, even

We’ll continue to take vigorous steps under #FDA’s Youth Tobacco Prevention Plan, using the full scope of our authorities, to target youth access to, and appeal of, these products. It’s a top priority of ours to prevent kids from getting hooked on nicotin

This will enhance protection of human research subjects and reduce the regulatory burden on the research community by creating efficiencies and strengthening standards in the clinical trial enterprise https://t.co/IDTIja2J80

#FDA is committed to protecting safety of people who participate in clinical trials https://t.co/IfkLOhrK30 Today we issued guidance w/HHS describing consistent approach to written procedures implemented by institutions & IRBs responsible for oversigh

#FDA will continue to update the new website we unveiled today with new inquiries we receive from generic manufacturers who identify to us that they are having difficulty accessing samples of branded drugs to conduct generic registration studies https://t

I want to thank @statnews for correcting the earlier version of their story on right to try by @ikeswetlitz that mischaracterized parts of our discussion; we appreciate the publication’s responsiveness

.@FDATobacco is planning consumer perception study to further inform its evaluation of potential modified risk tobacco products (MRTP). How the public understands the relative risk of tobacco-related disease is an important element of MRTP review: https:/

UPDATE on Romaine Lettuce: It is highly unlikely that product from the Yuma growing region is still in the supply chain. Consumers can be confident that romaine currently available for purchase is not part of the investigation. FDA continues to investigat

RT @CNBC: The FDA gave expedited approval for the first non-opioid treatment to ease withdrawal from quitting addictive opioi… https://t.co/WxAlNcQQsY

RT @FDAOncology: Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada https://t.co/8Rr3kcUxLM

RT @NYTHealth: The F.D.A. begins outing drug makers it claims refuse to share drug samples for cheaper generic copies of big-name… https://t.co/6B0pgXvmrj

Encouraging development of innovative products that may be less dangerous than cigarettes for adults who still seek nicotine is a cornerstone of #FDA’s comprehensive plan on tobacco & nicotine. This study aims to inform reviews of these potential prod

Safety and innovation for medical devices should go hand in hand. I believe the best technological advances should lead to more lives saved and fewer adverse events: https://t.co/ffiK7ELkOp So we’re creating new incentives for innovation that improves saf

#FDA is focused on striking right balance between reducing new opioid addiction and providing appropriate access to pain medicines. To address these goals/challenges, #FDA is holding a meeting on 7/9 focused solely on needs of those suffering chronic pain

Since establishing the Opioid Policy Steering Committee a year ago, #FDA has received wide range of feedback, including patient voices, affirming that as we address this crisis we cannot lose sight of the needs those living with chronic/end-of-life pain:

Evidence-based information to inform opioid prescribing can help curb overprescribing, maintain access to needed treatments. We’ll be taking new steps to encourage medical professional societies to develop guidelines on appropriate prescribing: https://t.

RT @ikeswetlitz: .@US_FDA will start naming companies that have been accused of slowing down generic drug development (but will not… https://t.co/tHybwD069b

RT @BioCentury: FDA will identify companies that have abused REMS agreements to thwart generic, biosimilar competition,… https://t.co/io3mEHU9hM

RT @JaredSHopkins: Obviously best sock game in all of government https://t.co/bmCUgxHv3t QT @EricTopol: When you're the @US_FDA Commissioner [@SGottliebFDA], your socks get noticed :-) https://t.co/5pigRV53aM https://t.co/E3y1ilZ8c4)

RT @steveusdin1: FDA is reorganizing the Office of New Drugs to stay ahead of drug development. Now posted in front of the paywall -… https://t.co/pU9QznhhTy

These are my skinniest socks. https://t.co/avFsOAn6w0 QT @EricTopol: When you're the @US_FDA Commissioner [@SGottliebFDA], your socks get noticed :-) https://t.co/5pigRV53aM https://t.co/E3y1ilZ8c4)

#FDA will unveil in June a major updating of the structure and function of its new drug review process to make it more modern, rigorous, to better integrate cross disciplinary science as part of collaborative teams, develop more focused review divisions

RT @SeemaCMS: Catch me LIVE tomorrow with @WashingtonPost discussing the future of #Medicaid and its effects on American health.… https://t.co/OkWgwDFs7y

RT @FDATobacco: If nobody smoked, 1 out of every 3 cancer deaths in the U.S. could be prevented. #DearFutureMe #NPW2018 https://t.co/59BrDf7aoG

RT @SeemaCMS: For the first time ever, the @CMSGov Drug Pricing Dashboard will now show year-over-year price changes for prescrip… https://t.co/vxf2ps10eG

RT @califf001: Important step forward. Modernizing without losing the demand for high quality evidence! https://t.co/XFHQaeGtmV QT @SGottliebFDA: #FDA will unveil in June a major updating of the structure and function of its new drug review process to make it m… https://t.co/FhXK1mowUe)

Make sure that any gene therapy has either been approved by FDA or is being studied under appropriate regulatory oversight. Get the facts: Learn more about gene therapy and how it works. https://t.co/qrwgTWuCsZ

#FDA is concerned about the safety risks involved in “DIY” gene therapy products intended for self-administration and “do it yourself” kits to produce gene therapies for self-administration. We warned the sale of these products is against the law. https:/

Learn about the participation of women in clinical trials for cardiovascular drugs in our new journal article. Read here: https://t.co/rHCGBWzr0j @JACCJournals #JACC #FDAGreatDebate https://t.co/YASsRuZIWE

#FDA is focused on the risks posed to Americans from drugs brought illegally into US; increasing FDA’s presence at IMFs, improving our intelligence gathering, increasing collaboration with partners. New funding and authorities will support these efforts h

RT @FDAWomen: Thank you to everyone who joined “The Great Debate: What is Enough… Women in Clinical Trials” webcast today! Learn… https://t.co/si5H8Ct9NR

While CDC recently updated the case count for the salmonella outbreak in eggs, these are old cases meaning the last new illness was from last month (April 14, 2018). https://t.co/JnRtLB9ZMN

#FDA inspected Rose Acre Farms last month and the company is taking corrective action. FDA is monitoring to ensure the appropriate action takes place. https://t.co/JnRtLB9ZMN

Federal health officials updated consumer advice today because it is highly unlikely that romaine lettuce from the Yuma growing region is still in the supply chain: https://t.co/We02xgGjGj

FDA & CDC remind consumers to not eat any of the recalled eggs from Rose Acre Farms. These eggs were recalled April 13 & 16 so stores should not have them for purchase. Eggs last about three weeks - consumers should check they don’t have recalled

We know romaine lettuce has not been shipped from the Yuma area since mid-April. Consumers can be confident that romaine currently available for purchase is not part of this outbreak investigation: https://t.co/We02xgGjGj

#FDA ruled out that the contamination was caused by just one farm suggesting it was a complex problem and will take further time to investigate https://t.co/We02xgGjGj Our goal is to find the source of this outbreak. We’ll use what we learn to improve our

RT @HHSMedia: HHS @SecAzar praises @US_FDA approval of first non-opioid treatment for opioid withdrawal https://t.co/x7R2uATqCb #opioids

#FDA is taking policy steps to help promote the development of new treatments for opioid addiction, to promote the use of MAT, and to address the stigma sometimes associated with safe and effective replacement therapy. Stigma can be a barrier to their use

RT @FDAWomen: Read @SGottliebFDA's full remarks from today's #FDAGreatDebate: https://t.co/pUZoZBY1G1

RT @ABC: "We will never see his like again": 81-year-old whose blood donations have helped save over 2 million babies donate… https://t.co/M85PMSwBFR

RT @NIIMBL: @US_FDA Deputy Commissioner for Policy, Legislation, and Analysis, Anna Abram, discusses FDA support for the develo… https://t.co/WTPoYOc4fr

https://t.co/97a8BXqndi

RT @FDATobacco: Today, FDA sent official information requests to four e-cig manufacturers. The companies must respond by July 12… https://t.co/pvFKvkSiJr

RT @FDAMedia: FDA requires additional e-cigarette makers to provide critical information so the agency can better examine youth u… https://t.co/9kMGpEpGiZ

@alikodjakNPR @sangerkatz @PeterSullivan4 @porszag @SecAzar But our discussion was about Part D. In Part D people choose plans in a large marketplace. Even in the employer ASO market there’s choice. True sometimes employers only offer a single option, but

The letters to more e-cigarette makers follow a similar request #FDA sent to JUUL Labs last month. We’ll explore all regulatory options, including enforcement actions, based on what we learn from the information these manufacturers are required to provide

RT @FDAMedia: Statement from @SGottliebFDA on new agency efforts to shine light on situations where drug makers may be pursuing g… https://t.co/pmd86YTlgb

Too many kids continue to experiment with e-cigarette and vaping products, and it’s critical that we take aggressive steps to address it. This includes taking a hard look at whether certain design features/product marketing practices are fueling youth use

Today #FDA is continuing to take important steps under our Youth Tobacco Prevention Plan by requiring four additional e-cigarette makers to provide critical information so the agency can better examine youth use and product appeal: https://t.co/KdVzyo6YbU

@alikodjakNPR @sangerkatz @PeterSullivan4 @porszag @SecAzar The bigger change we’ve seen in recent years, IMHO, is the wider adoption of “closed” formularies. I don’t have data but am pretty sure they’re far more common today than they were pre-ACA, even

We’ll continue to take vigorous steps under #FDA’s Youth Tobacco Prevention Plan, using the full scope of our authorities, to target youth access to, and appeal of, these products. It’s a top priority of ours to prevent kids from getting hooked on nicotin

This will enhance protection of human research subjects and reduce the regulatory burden on the research community by creating efficiencies and strengthening standards in the clinical trial enterprise https://t.co/IDTIja2J80

#FDA is committed to protecting safety of people who participate in clinical trials https://t.co/IfkLOhrK30 Today we issued guidance w/HHS describing consistent approach to written procedures implemented by institutions & IRBs responsible for oversigh

#FDA will continue to update the new website we unveiled today with new inquiries we receive from generic manufacturers who identify to us that they are having difficulty accessing samples of branded drugs to conduct generic registration studies https://t

I want to thank @statnews for correcting the earlier version of their story on right to try by @ikeswetlitz that mischaracterized parts of our discussion; we appreciate the publication’s responsiveness

.@FDATobacco is planning consumer perception study to further inform its evaluation of potential modified risk tobacco products (MRTP). How the public understands the relative risk of tobacco-related disease is an important element of MRTP review: https:/

UPDATE on Romaine Lettuce: It is highly unlikely that product from the Yuma growing region is still in the supply chain. Consumers can be confident that romaine currently available for purchase is not part of the investigation. FDA continues to investigat

RT @CNBC: The FDA gave expedited approval for the first non-opioid treatment to ease withdrawal from quitting addictive opioi… https://t.co/WxAlNcQQsY

RT @FDAOncology: Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada https://t.co/8Rr3kcUxLM

RT @NYTHealth: The F.D.A. begins outing drug makers it claims refuse to share drug samples for cheaper generic copies of big-name… https://t.co/6B0pgXvmrj

Encouraging development of innovative products that may be less dangerous than cigarettes for adults who still seek nicotine is a cornerstone of #FDA’s comprehensive plan on tobacco & nicotine. This study aims to inform reviews of these potential prod